Stéphane Pion
Directeur/Membre du Conseil chez PainCeptor Pharma Corp.
Postes actifs de Stéphane Pion
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
PainCeptor Pharma Corp.
 PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Stéphane Pion
Anciens postes connus de Stéphane Pion
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Transfer Technologies Commercialisation Capital
 Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Analyste en capital-investissement | 01/01/1998 | - |
Formation de Stéphane Pion
| University of Montréal | Doctorate Degree |
Statistiques
Internationale
| Canada | 4 |
Opérationnelle
| Private Equity Analyst | 1 |
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Finance | 2 |
| Health Technology | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Transfer Technologies Commercialisation Capital
Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Finance |
PainCeptor Pharma Corp.
PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Health Technology |
- Bourse
- Insiders
- Stéphane Pion
- Expérience
